The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Trifluridine/tipiracil plus bevacizumab (FTD/TPI + BEV) and trifluridine/tipiracil (FTD/TPI) monotherapy in metastatic colorectal cancer (mCRC): Results of a meta-analysis.
 
Takayuki Yoshino
Honoraria - Bayer Yakuhin; Chugai Pharma; Merck; MSD K.K.; Ono Pharmaceutical
Research Funding - Amgen (Inst); Chugai Pharma (Inst); DAIICHI SANKYO COMPANY, LIMITED (Inst); Genomedia (Inst); MSD (Inst); Nippon Boehringer Ingelheim (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sanofi (Inst); Sysmex (Inst); Taiho Pharmaceutical (Inst)
 
Julien Taieb
Consulting or Advisory Role - Amgen; Merck KGaA; MSD; Novartis; Pierre Fabre; Roche; SERVIER
Speakers' Bureau - Amgen; Lilly; Merck; MSD; Pierre Fabre; Roche/Genentech; Sanofi; SERVIER
 
Thierry Andre
Honoraria - AMGEN; Bristol-Myers Squibb; GlaxoSmithKline; Merck; Pierre Fabre; Roche/Genentech; SERVIER; Ventana Medical Systems
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca/MedImmune; Bristol-Myers Squibb; GamaMabs Pharma; GlaxoSmithKline; Gritstone Bio; Kaleido Biosciences; MSD Oncology; Pierre Fabre; Seagen; SERVIER; Servier; Tesaro; Transgene
Travel, Accommodations, Expenses - MSD Oncology
(OPTIONAL) Uncompensated Relationships - Adjuvant Colon Cancer End Points (ACCENT) Collaborative Group; ARCAD Foundation; Gercor
 
Yasutoshi Kuboki
Honoraria - Bayer; Bristol-Myers Squibb Japan; Lilly Japan; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - Amgen; Boehringer Ingelheim; Takeda
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Janssen Oncology (Inst); Lilly (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Per Pfeiffer
No Relationships to Disclose
 
Amit Kumar
Employment - Novartis
Consulting or Advisory Role - BMS (Inst); Taiho Pharmaceutical (Inst)
 
Howard S. Hochster
Stock and Other Ownership Interests - Compass Therapeutics; Processa Pharmaceuticals
Consulting or Advisory Role - Bayer; Genentech; Merck
Speakers' Bureau - Natera